VivoSeq
Other

Nasolabial Folds

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Nasolabial Folds is an early-stage landscape with 0 programs across 3 companies. The most active players are Topokine Therapeutics, Inc., Sanofi, Merz Pharmaceuticals GmbH.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Topokine Therapeutics, Inc.

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalM

Merz Pharmaceuticals GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Unknown status2 · 29%
Not yet recruiting1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Safety Study of TPX-121 on Nasolabial Folds
Active, not recruiting·TTego Science, Inc.·Phase 1·NCT06533540·18 enrolled
Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds
Not yet recruiting·JJetema Co., Ltd.·N/A·NCT07265791·100 enrolled
A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)
Completed·Sanofi logoSanofi·Phase 3·NCT00444626·140 enrolled
Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds
Completed·MMerz Pharmaceuticals GmbH·Phase 4·NCT00429520·114 enrolled
Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds
Completed·TThe New York Eye & Ear Infirmary·Phase 1/2·NCT00874094·15 enrolled
Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds
Unknown status·TTopokine Therapeutics, Inc.·Phase 2·NCT02607670·111 enrolled
Transplantation of Fibroblast for Correction of Nasolabial Folds
Unknown status·SSCARM Institute, Tabriz, Iran·Phase 1/2·NCT03140319·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)